SPIKE-1 is a Phase 2/3 trial looking at the use of Camostat to reduce the progression of symptoms of coronavirus (COVID-19).
The University of Edinburgh is part of the multisite clinical trial of an antiviral treatment which is led by Professor Kev Dhaliwal from the Centre for Inflammation Research. The study is conducted in collaboration with colleagues from the University of Oxford and Latus Therapeutics, managed by Cancer Research UK (CRUK) and funded by LifeArc.
If you have tested positive for COVID-19 you may be eligible to take part in this study.
Taking part in the study
The CRUK website provides more information and details of how to register your interest, or alternatively you can email us for more information.
Register your interest in SPIKE-1
Please consider joining our other COVID community study which involves completing online questionnaires regarding your COVID-19 experience. This also allows you to register interest for other suitable studies.
If you are over 16 and have been seen at an NHS service such as
- a COVID-19 Community Hub
- a drive-through testing service in NHS Lothian
- a Track and Trace app
which provides advice for people with potential symptoms of COVID-19, then you are eligible for this study.